Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02085070 · ClinicalTrials.gov registry record · Phase 2
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
A Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT02085070 is a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma that has completed, run by Yale University. The registered enrollment target is 65 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02085070, a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this trial is to study the activity of MK-3475 in untreated brain metastases from melanoma or non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG MK-3475
Study Locations (1)
Connecticut
- Smilow Cancer Center at Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2014-03 |
| Est. Completion | 2020-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02085070
The ClinicalTrials.gov registry entry for NCT02085070 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which MK-3475 is the first listed.
NCT02085070 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02085070 about?
NCT02085070 is a clinical study titled "MK-3475 in Melanoma and NSCLC Patients With Brain Metastases". The purpose of this trial is to study the activity of MK-3475 in untreated brain metastases from melanoma or non-small cell lung cancer.
What is the current status of trial NCT02085070?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2014-03. Estimated completion is 2020-02-27.
What conditions does trial NCT02085070 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Brain Metastases.
What interventions are being tested in trial NCT02085070?
The interventions under investigation include: MK-3475 (DRUG).
Who is sponsoring clinical trial NCT02085070?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02085070 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.